Ba D.M., Ssentongo P., Pelucchi C., Negri E., Palli D., …, Muscat J. Mushroom consumption and risk of gastric cancer: a pooled analysis within the stomach cancer pooling project and a combined meta-analysis with other observational studies. Eur J Cancer Prev. 2023;32(3):222-228.
Rationale
Ba's earlier 2021 meta-analysis (our mushroom-consumption-cancer-meta-2021 card) linked mushroom intake to lower overall cancer risk; here the same group does a targeted analysis on individual-level data for gastric cancer — stronger than a meta-analysis of published summary estimates.
Methods
Pooled analysis of individual data from 11 StoP (Stomach cancer Pooling) studies: 3,900 gastric cancer cases and 7,792 controls. Mushroom intake by food-frequency questionnaires; adjusted for age, sex, education, smoking, alcohol and calories. Plus a combined meta-analysis with 4 previously published studies.
Results
- High mushroom intake ↔ lower gastric cancer risk: RR 0.82 (0.71–0.95) highest vs lowest category.
- Across the four earlier studies: RR 0.59 (0.26–1.33 — non-significant).
- Across all data: RR 0.77 (0.66–0.91).
- The association held by sex and by histologic and anatomic subtype (cardia and non-cardia).
Authors' conclusions
High mushroom consumption is associated with reduced gastric cancer risk in the largest pooled individual dataset to date.
Worth noting
Individual-data pooled analysis is the strongest observational design available: unified variable recoding, standardised adjustments, less publication skew. But these are still observational data: mushroom consumption correlates with many other factors (lifestyle, income, overall diet), and causality is unproven. Mushrooms are not "protection" — they are one marker of a dietary pattern associated with lower risk.